Literature DB >> 22745238

Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.

Dick C Chan1, Anh Hoang, P Hugh R Barrett, Annett T Y Wong, Paul J Nestel, Dmitri Sviridov, Gerald F Watts.   

Abstract

CONTEXT: Cellular cholesterol efflux is a key step in reverse cholesterol transport and may depend on the metabolism of apolipoprotein (apo) B-100, apoA-I, and apoA-II.
OBJECTIVE: We examined the associations between cholesterol efflux and plasma concentrations and kinetics of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL)-apoB-100, high-density lipoprotein (HDL)-apoA-I, and HDL-apoA-II in men. DESIGN, SUBJECTS, AND METHODS: Thirty men were recruited from the community with a wide range of body mass index. The capacity of plasma and HDL to efflux cholesterol was measured ex vivo. Apolipoprotein kinetics were measured using stable isotope techniques and multicompartmental modeling.
RESULTS: Cholesterol efflux to whole plasma was correlated with plasma levels of cholesterol, triglyceride, apoB-100, insulin, cholesteryl ester transfer protein, and lecithin-cholesterol acyltransferase, body mass index and waist circumference (P < 0.05 in all). Cholesterol efflux was inversely correlated with the fractional catabolic rate (FCR) of VLDL (r = -0.728), IDL (r = -0.662), and LDL-apoB-100 (r = -0.479) but positively correlated with the FCR (r = 0.438) and production rate (r = 0.468) of HDL-apoA-II. In multiple regression analysis, the concentration and FCR of VLDL-apoB-100 (β-coefficient = 0.708 and -0.518, respectively) and IDL-apoB-100 (β-coefficient = 0.354 and -0.447, respectively) were independent predictors of cholesterol efflux. The association of cholesterol efflux with apoB-100 metabolism was diminished after removal of apoB-100-containing lipoproteins from plasma prior to efflux. All associations, except for cholesteryl ester transfer protein, were lost when cholesterol efflux to isolated HDL was tested.
CONCLUSIONS: The plasma concentration and kinetics of apoB-100-containing lipoproteins are significant predictors of the capacity of whole plasma to effect cellular cholesterol efflux.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22745238     DOI: 10.1210/jc.2012-1522

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes.

Authors:  Hussein N Yassine; Alexandra Belopolskaya; Christina Schall; Craig S Stump; Serrine S Lau; Peter D Reaven
Journal:  Metabolism       Date:  2014-03-05       Impact factor: 8.694

2.  Proteomics reveals age-related differences in the host immune response to sepsis.

Authors:  Zhiyun Cao; Sachin Yende; John A Kellum; Derek C Angus; Renã A S Robinson
Journal:  J Proteome Res       Date:  2013-12-04       Impact factor: 4.466

3.  Determinants of HDL Cholesterol Efflux Capacity after Virgin Olive Oil Ingestion: Interrelationships with Fluidity of HDL Monolayer.

Authors:  Sara Fernández-Castillejo; Laura Rubió; Álvaro Hernáez; Úrsula Catalán; Anna Pedret; Rosa-M Valls; Juana I Mosele; Maria-Isabel Covas; Alan T Remaley; Olga Castañer; Maria-José Motilva; Rosa Solá
Journal:  Mol Nutr Food Res       Date:  2017-10-26       Impact factor: 5.914

4.  Association of Cholesterol Efflux Capacity With Clinical Features of Metabolic Syndrome: Relevance to Atherosclerosis.

Authors:  Julie Gall; Eric Frisdal; Randa Bittar; Wilfried Le Goff; Eric Bruckert; Philippe Lesnik; Maryse Guerin; Philippe Giral
Journal:  J Am Heart Assoc       Date:  2016-11-23       Impact factor: 5.501

5.  Bilirubin Decreases Macrophage Cholesterol Efflux and ATP-Binding Cassette Transporter A1 Protein Expression.

Authors:  Dongdong Wang; Anela Tosevska; Elke H Heiß; Angela Ladurner; Christine Mölzer; Marlies Wallner; Andrew Bulmer; Karl-Heinz Wagner; Verena M Dirsch; Atanas G Atanasov
Journal:  J Am Heart Assoc       Date:  2017-04-28       Impact factor: 5.501

6.  Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?

Authors:  Qidi Ying; Annalisa Ronca; Dick C Chan; Jing Pang; Elda Favari; Gerald F Watts
Journal:  Eur J Clin Invest       Date:  2022-03-24       Impact factor: 5.722

7.  Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography.

Authors:  Hiroko Inoue; Yuhei Shiga; Kenji Norimatsu; Kohei Tashiro; Makito Futami; Yasunori Suematsu; Makoto Sugihara; Hiroaki Nishikawa; Yousuke Katsuda; Shin-Ichiro Miura
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

8.  Tachometer for reverse cholesterol transport?

Authors:  Arnold Eckardstein
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

9.  Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry.

Authors:  Zsuzsanna Kuklenyik; Jeffery I Jones; Michael S Gardner; David M Schieltz; Bryan A Parks; Christopher A Toth; Jon C Rees; Michael L Andrews; Kayla Carter; Antony K Lehtikoski; Lisa G McWilliams; Yulanda M Williamson; Kevin P Bierbaum; James L Pirkle; John R Barr
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.